
View larger version (111K):
[in a new window]
|
Fig. 7. HA-Sec8 localization in late-stage egg chambers. HA-Sec8 was expressed exclusively in the germ line under the control of nanos-Gal4. (A,B) Egg chambers from sec5E13/+ heterozygous controls at stage 7 are labeled with anti-Sec5 antibody (A) or anti-HA antibody and Texas-Red/phalloidin (B). Sec5 and HA-Sec8 both concentrate along the oocyte (*) membrane. Probably owing to overexpression, HA-Sec8 often accumulates in the cytoplasm of some nurse cells. (C-E) Egg chambers from sec5E13/+ heterozygous controls at stage 10 are labeled with Hoechst 33342 and anti-Sec5 antibody (C) or anti-HA antibody and Texas Red-phalloidin (D,E). Sec5 and HA-Sec8 concentrate at anterior corners (arrows) of the oocyte membrane. (F-H) Egg chambers from sec5E13 homozygous germ lines are labeled with Hoechst 33342 and Texas Red-phalloidin (F-H) and with anti-HA antibody (G,H). HA-Sec8 no longer concentrates at the oocyte (*) membrane but rather fills the oocyte cytosol when Sec5 function is compromised by the mutation. In addition, the sec5E13 phenotype (F) is enhanced by the presence of the HA-sec8 transgene (G,H), stunting the oocyte, disrupting nurse cell membranes and causing ring canals to clump together. (I,J) GFP egg chambers from FRT42D sec6Ex15 homozygous germ lines, generated by mitotic recombination with FRT42D Ubi-GFP. GFP is shown in green (I1,J1). HA-Sec8 (red in I1,J1 and green in I2,J2) accumulates in puncta within the mutant egg chambers and in proximity to actin-rich ring canals (red in I2,J2). All scale bars are 20 µm.
|